About Us
Devoted to developing innovative gene and cell therapies for curing malignant tumors
Established in Haidian, Beijing
Awarded "Zhongguancun Golden Seed Company" and "Zhongguancun High and New Tech Enterprise"
Received Angel Series Investments from Cowin Capital and Tsinghua University x-lab DNA fund
Honored "National High and New Tech Enterprise"
Honored " Young Eagle Talent" of Beijing (Dr. Ting He, the co-founder)
Won the "Tsinghua University President Cup Innovation Challenge Gold Award"
Won the "Tsinghua University x-lab Star of the Year"
Received Series A investment from Thiel Capital, BSTIG, Shengjing360
Honored "Beijing Science and Technology Rising Star" (Dr. Ting He)
Received Series B investment from Legend Capital, Thiel Capital, Shengjing360
Awarded funds from “G20 Engineering Pharmaceutical Industry Innovative R&D”
Honored "Zhongguancun High-End Leading Talents" (Dr. Ting He and Dr. Xinan Lu, co-founders)
Awarded "Top 50 Most Valuable Investment Enterprises in China" by Zero2IPO Group
Presentation at 60th ASH Annual Meeting
Won the "Creative Youth" Zhejiang University
Double-Creative Cup Entrepreneurship Competition Golden Award
Awarded funds from "Zhongguancun Frontier Reserve Project"
Received Series C Investment from Shougang fund, Sherpa Capital, China Resources Innovation Capital, Qing Zhe Capital , Thiel Capital
Honored "Zhongguancun High-End Leading Talent" and Beijing "Science and Technology Rising Star" (Dr. Feifei Qi, the co-founder)
Honored “Life Science Innovator of the Year” by DeepTech (Dr. Ting He)
Awarded the Star Award 2019’s Top 50 Most Innovative Companies in Chinese Biomedicine Industry
Awarded the Entrepreneurship Award 2019’s China's Top 50 Healthcare Innovation Companies
Awarded the Pencil Road 2019’s Real List of TOP50 Quasi-Unicorn Companies of Era Influence
IM19 product received two IND approvals for relapsed or refractory B-cell acute lymphocytic leukemia and relapsed or refractory non-Hodgkin's lymphoma
Achieved strategic cooperation with Edigene
Achieved strategic cooperation with Simcere Pharmaceutical
Received Series C+ investment from Longmen Fund
IM19 received the third IND approved
Cooperatet research and development center for CAR T cell therapy with Peking University Third Hospital
Cooperate Beijing Engineering Research Center for the development of new anti-tumor drugs and new technologies with Beijing Cancer Hospital
Received Series D investment from China Life Private Equity Investment Company Limited
Approved Post-Doctoral Research Center
Approved the title of the specialized and innovative enterprise in Beijing
Approved the first holder of Drug Production License for gene and cell drugs in Beijing
Received Series D+ investment from Beijing Zhongguancun Science City Company and North Venture Capital
Approved the Grand Final of the National Disruptive Technology Innovation Competition
Taiping Innovation Investment of China Taiping become a shareholder
Received the fourth CAR-T IND approved
ZM001 for SLE received the IND approved
IM96 for mCRC received the IND approved
IM19 completes the largest CGT deal with Huadong in China 2024
